Payment overview · 2025
General Payments
$3,468.36
144 reported records · 29 companies
Healthcare provider profile · identity verified
Marina Neystat, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FOREST HILLS, NY · NPI 1124013990
Verified facts
What the public records show
CMS Open Payments records show Marina Neystat, M.D. received $3,468.36 in general payments during 2025 across 144 reported records.
ABBVIE INC. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gocovri, Horizant, Nurtec Odt, Qulipta, Trintellix, Ubrelvy, Valtoco, Vumerity, Vyepti, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Rytary by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 554 claims for Horizant by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYEPTI as an associated drug or biological on 30327 records involving 8800 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vyepti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gocovri by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ampyra by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Valtoco by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 642 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Ztlido by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Trintellix by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $540.54 | 15.6% | 22 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $431.12 | 12.4% | 16 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $237.28 | 6.8% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $235.35 | 6.8% | 13 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $217.46 | 6.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $187.10 | 5.4% | 10 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $162.02 | 4.7% | 5 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$159.75 | 4.6% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $110.62 | 3.2% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $97.64 | 2.8% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $95.48 | 2.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $93.85 | 2.7% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $91.19 | 2.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $90.17 | 2.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.48 | 2.2% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $76.03 | 2.2% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.07 | 2.1% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $63.20 | 1.8% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$61.85 | 1.8% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $58.80 | 1.7% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.66 | 1.5% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $46.62 | 1.3% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $46.48 | 1.3% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.02 | 1.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.49 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.01 | 0.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.12 | 0.7% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $23.88 | 0.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.08 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,468.36 | 144 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $400.76 | 15 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $387.12 | 14 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $237.28 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $235.35 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $235.35 | 13 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $187.10 | 10 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $163.42 | 7 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $162.02 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $110.61 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $97.64 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $93.85 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $90.17 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $76.48 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $76.03 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $74.63 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $74.07 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $70.49 | 3 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $65.06 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $63.20 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $61.85 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $58.80 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $54.32 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $54.04 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $51.66 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $51.14 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $46.62 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $46.48 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $35.99 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $31.72 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $8.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 84 | exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 554 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 642 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 296 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 285 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 279 | exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 20 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYEPTI vyepti |
2025 | Vyepti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 353 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
84 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
296 | 54 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
279 | 49 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
265 | 38 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
554 | 78 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | VYEPTI open payments reported associated product |
CMS Open Payments — General Payments 30327 supporting records · 8800 recipient NPIs · example record 1251760014 |
Vyepti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
178 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
642 | 120 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
353 | 75 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
285 | 48 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Duloxetine Hcl | Duloxetine Hcl | 1098 | 190 |
| Memantine Hcl Er | Memantine Hcl | 744 | 133 |
| Gabapentin | Gabapentin | 646 | 162 |
| Nurtec Odt | Rimegepant Sulfate | 642 | 120 |
| Horizant | Gabapentin Enacarbil | 554 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 543 | 95 |
| Diclofenac Sodium | Diclofenac Sodium | 532 | 98 |
| Memantine Hcl | Memantine Hcl | 466 | 79 |
| Trazodone Hcl | Trazodone Hcl | 406 | 89 |
| Gralise | Gabapentin | 353 | 56 |
| Ztlido | Lidocaine | 353 | 75 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 328 | 49 |
| Meloxicam | Meloxicam | 299 | 159 |
| Qulipta | Atogepant | 296 | 54 |
| Trintellix | Vortioxetine Hydrobromide | 285 | 48 |
| Ondansetron Odt | Ondansetron | 282 | 173 |
| Pregabalin | Pregabalin | 279 | 53 |
| Ubrelvy | Ubrogepant | 279 | 49 |
| Nortriptyline Hcl | Nortriptyline Hcl | 276 | 60 |
| Neupro | Rotigotine | 268 | 50 |
| Rytary | Carbidopa/Levodopa | 265 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 248 | 52 |
| Donepezil Hcl | Donepezil Hcl | 238 | 46 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 227 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 210 | 37 |
| Emgality Pen | Galcanezumab-Gnlm | 206 | 30 |
| Lidocaine | Lidocaine | 201 | 37 |
| Clonazepam | Clonazepam | 197 | 57 |
| Propranolol Hcl Er | Propranolol Hcl | 194 | 32 |
| Midodrine Hcl | Midodrine Hcl | 188 | 46 |
| Propranolol Hcl | Propranolol Hcl | 181 | 37 |
| Topiramate | Topiramate | 179 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 179 | 35 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 178 | 33 |
| Primidone | Primidone | 172 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 146 | 35 |
| Rizatriptan | Rizatriptan Benzoate | 142 | 28 |
| Levetiracetam | Levetiracetam | 135 | 18 |
| Aimovig Autoinjector | Erenumab-Aooe | 125 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 17 |
| Sertraline Hcl | Sertraline Hcl | 114 | 20 |
| Rivastigmine | Rivastigmine | 106 | 17 |
| Mirtazapine | Mirtazapine | 100 | 20 |
| Belsomra | Suvorexant | 89 | 31 |
| Methylprednisolone | Methylprednisolone | 89 | 82 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | suppressed |
| Zonisamide | Zonisamide | 86 | 15 |
| Botox | Onabotulinumtoxina | 84 | 29 |
| Lamictal Xr | Lamotrigine | 79 | suppressed |
| Droxidopa | Droxidopa | 77 | 11 |
| Temazepam | Temazepam | 75 | 22 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 71 | 15 |
| Northera | Droxidopa | 70 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 68 | 37 |
| Alprazolam | Alprazolam | 68 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 14 |
| Briviact | Brivaracetam | 65 | suppressed |
| Bupropion Xl | Bupropion Hcl | 64 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 64 | 14 |
| Trokendi Xr | Topiramate | 63 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 61 | 15 |
| Diclofenac Potassium | Diclofenac Potassium | 60 | 23 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 58 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 11 |
| Desipramine Hcl | Desipramine Hcl | 54 | 13 |
| Lorazepam | Lorazepam | 54 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Savella | Milnacipran Hcl | 52 | suppressed |
| Naproxen | Naproxen | 51 | 20 |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Lamotrigine Er | Lamotrigine | 49 | suppressed |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Cymbalta | Duloxetine Hcl | 44 | suppressed |
| Keppra Xr | Levetiracetam | 43 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | 14 |
| Aptiom | Eslicarbazepine Acetate | 38 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 37 | 12 |
| Ingrezza | Valbenazine Tosylate | 36 | suppressed |
| Nadolol | Nadolol | 36 | suppressed |
| Ongentys | Opicapone | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Carbamazepine Er | Carbamazepine | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Trileptal | Oxcarbazepine | 32 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Treximet | Sumatriptan Succ/Naproxen Sod | 31 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 29 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 29 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 28 | suppressed |
| Zolmitriptan | Zolmitriptan | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Diazepam | Diazepam | 27 | 12 |
| Licart | Diclofenac Epolamine | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 25 | suppressed |
| Gocovri | Amantadine Hcl | 25 | suppressed |
| Ramelteon | Ramelteon | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 23 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 22 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Reyvow | Lasmiditan Succinate | 22 | suppressed |
| Xcopri | Cenobamate | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Lexapro | Escitalopram Oxalate | 20 | suppressed |
| Nexium | Esomeprazole Magnesium | 20 | suppressed |
| Seroquel | Quetiapine Fumarate | 20 | suppressed |
| Valtoco | Diazepam | 20 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 19 | suppressed |
| Lamictal | Lamotrigine | 19 | suppressed |
| Viibryd | Vilazodone Hcl | 19 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 18 | suppressed |
| Flector | Diclofenac Epolamine | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ampyra | Dalfampridine | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 17 | suppressed |
| Neurontin | Gabapentin | 17 | suppressed |
| Topiramate Er | Topiramate | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Vimpat | Lacosamide | 15 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Seglentis | Tramadol Hcl/Celecoxib | 14 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Abilify | Aripiprazole | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Elyxyb | Celecoxib | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Pregabalin Er | Pregabalin | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Vumerity | Diroximel Fumarate | 13 | suppressed |
| Vyepti | Eptinezumab-Jjmr | 13 | suppressed |
| Depakote Er | Divalproex Sodium | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Migranal | Dihydroergotamine Mesylate | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Topamax | Topiramate | 12 | suppressed |
| Azilect | Rasagiline Mesylate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Pristiq | Desvenlafaxine Succinate | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Zolmitriptan Odt | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,468.36 · 144 records | ABBVIE INC. | ACTHAR, AVEIR, BOTOX, BRIUMVI, CREXONT, EPIDIOLEX, Fintepla, Gocovri, HORIZANT, HYQVIA, INBRIJA, JOURNAVX, KESIMPTA, LEQEMBI, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, WAKIX, Xeomin, ZAVZPRET, ZEPOSIA, ZTLido | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error